TK1 and breast cancer: It was found that TK1 levels and TK activity (TKa) are reduced after treatment with palbociclib only in sensitive ER+ BC cell lines and that low TKa at baseline measured in plasma samples from patients enrolled in the TREnd trial (NCT02549430) was correlated with longer PFS [145].